vs
Natural Grocers by Vitamin Cottage, Inc.（NGVC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Natural Grocers by Vitamin Cottage, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$335.6M vs $207.3M），Natural Grocers by Vitamin Cottage, Inc.净利率更高（3.4% vs -62.0%，领先65.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 1.6%），Natural Grocers by Vitamin Cottage, Inc.自由现金流更多（$11.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.4%）
Natural Grocers by Vitamin Cottage, Inc.是美国本土的特色零售连锁企业，主营认证有机食品、膳食补充剂、天然个护及环保家居类产品，面向健康意识较强的消费群体，门店覆盖美国多州，执行严格品控标准，拒绝售卖含人工添加剂的商品。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NGVC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $335.6M | $207.3M |
| 净利润 | $11.3M | $-128.6M |
| 毛利率 | 29.5% | — |
| 营业利润率 | 4.4% | -54.7% |
| 净利率 | 3.4% | -62.0% |
| 营收同比 | 1.6% | 25.9% |
| 净利润同比 | 14.0% | 3.5% |
| 每股收益（稀释后） | $0.49 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $335.6M | $207.3M | ||
| Q3 25 | $336.1M | $159.9M | ||
| Q2 25 | $328.7M | $166.5M | ||
| Q1 25 | $335.8M | $139.3M | ||
| Q4 24 | $330.2M | $164.6M | ||
| Q3 24 | $322.7M | $139.5M | ||
| Q2 24 | $309.1M | $147.0M | ||
| Q1 24 | $308.1M | $108.8M |
| Q4 25 | $11.3M | $-128.6M | ||
| Q3 25 | $11.8M | $-180.4M | ||
| Q2 25 | $11.6M | $-115.0M | ||
| Q1 25 | $13.1M | $-151.1M | ||
| Q4 24 | $9.9M | $-133.2M | ||
| Q3 24 | $9.0M | $-133.5M | ||
| Q2 24 | $9.2M | $-131.6M | ||
| Q1 24 | $8.0M | $-170.7M |
| Q4 25 | 29.5% | — | ||
| Q3 25 | 29.5% | — | ||
| Q2 25 | 29.9% | — | ||
| Q1 25 | 30.3% | — | ||
| Q4 24 | 29.9% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.2% | — | ||
| Q1 24 | 29.3% | — |
| Q4 25 | 4.4% | -54.7% | ||
| Q3 25 | 4.6% | -106.9% | ||
| Q2 25 | 4.7% | -64.8% | ||
| Q1 25 | 5.2% | -102.6% | ||
| Q4 24 | 4.0% | -74.3% | ||
| Q3 24 | 3.7% | -94.6% | ||
| Q2 24 | 4.2% | -79.1% | ||
| Q1 24 | 3.7% | -151.9% |
| Q4 25 | 3.4% | -62.0% | ||
| Q3 25 | 3.5% | -112.8% | ||
| Q2 25 | 3.5% | -69.0% | ||
| Q1 25 | 3.9% | -108.5% | ||
| Q4 24 | 3.0% | -80.9% | ||
| Q3 24 | 2.8% | -95.7% | ||
| Q2 24 | 3.0% | -89.5% | ||
| Q1 24 | 2.6% | -156.8% |
| Q4 25 | $0.49 | $-1.28 | ||
| Q3 25 | $0.51 | $-1.81 | ||
| Q2 25 | $0.50 | $-1.17 | ||
| Q1 25 | $0.56 | $-1.57 | ||
| Q4 24 | $0.43 | $-1.34 | ||
| Q3 24 | $0.38 | $-1.40 | ||
| Q2 24 | $0.40 | $-1.52 | ||
| Q1 24 | $0.35 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $220.0M | $-80.0M |
| 总资产 | $668.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $23.2M | $421.0M | ||
| Q3 25 | $17.1M | $202.5M | ||
| Q2 25 | $13.2M | $176.3M | ||
| Q1 25 | $21.2M | $127.1M | ||
| Q4 24 | $6.3M | $174.0M | ||
| Q3 24 | $8.9M | $150.6M | ||
| Q2 24 | $13.9M | $480.7M | ||
| Q1 24 | $11.0M | $112.3M |
| Q4 25 | $220.0M | $-80.0M | ||
| Q3 25 | $212.4M | $9.2M | ||
| Q2 25 | $202.5M | $151.3M | ||
| Q1 25 | $193.0M | $144.2M | ||
| Q4 24 | $181.9M | $255.0M | ||
| Q3 24 | $174.3M | $346.8M | ||
| Q2 24 | $167.8M | $432.4M | ||
| Q1 24 | $160.0M | $140.3M |
| Q4 25 | $668.6M | $1.5B | ||
| Q3 25 | $670.5M | $1.2B | ||
| Q2 25 | $659.0M | $1.3B | ||
| Q1 25 | $664.6M | $1.3B | ||
| Q4 24 | $648.9M | $1.5B | ||
| Q3 24 | $655.5M | $1.5B | ||
| Q2 24 | $654.4M | $1.6B | ||
| Q1 24 | $656.6M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $11.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 3.4% | -48.6% |
| 资本支出强度资本支出/营收 | 2.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.86× | — |
| 过去12个月自由现金流最近4个季度 | $42.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $21.1M | $-99.8M | ||
| Q3 25 | $15.6M | $-91.4M | ||
| Q2 25 | $2.9M | $-108.3M | ||
| Q1 25 | $34.1M | $-166.5M | ||
| Q4 24 | $2.7M | $-79.3M | ||
| Q3 24 | $24.5M | $-67.0M | ||
| Q2 24 | $12.4M | $-77.0M | ||
| Q1 24 | $20.2M | $-190.7M |
| Q4 25 | $11.6M | $-100.8M | ||
| Q3 25 | $7.5M | $-92.7M | ||
| Q2 25 | $-4.2M | $-110.7M | ||
| Q1 25 | $27.6M | $-167.8M | ||
| Q4 24 | $-6.9M | $-79.5M | ||
| Q3 24 | $18.0M | $-68.6M | ||
| Q2 24 | $3.6M | $-79.0M | ||
| Q1 24 | $9.8M | $-193.9M |
| Q4 25 | 3.4% | -48.6% | ||
| Q3 25 | 2.2% | -58.0% | ||
| Q2 25 | -1.3% | -66.5% | ||
| Q1 25 | 8.2% | -120.5% | ||
| Q4 24 | -2.1% | -48.3% | ||
| Q3 24 | 5.6% | -49.2% | ||
| Q2 24 | 1.2% | -53.7% | ||
| Q1 24 | 3.2% | -178.2% |
| Q4 25 | 2.9% | 0.5% | ||
| Q3 25 | 2.4% | 0.8% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 1.9% | 1.0% | ||
| Q4 24 | 2.9% | 0.1% | ||
| Q3 24 | 2.0% | 1.2% | ||
| Q2 24 | 2.9% | 1.4% | ||
| Q1 24 | 3.4% | 3.0% |
| Q4 25 | 1.86× | — | ||
| Q3 25 | 1.32× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 2.60× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 2.72× | — | ||
| Q2 24 | 1.35× | — | ||
| Q1 24 | 2.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
